Volume : 6, Issue : 6, June - 2017

EXPERIENCE WITH ANTI-FUNGALS IN OUR NICU

Anjali Edbor, Himanshu Dua, Praman Kushwah

Abstract :

<p>&nbsp;<span style="text-align: justify; font-family: &quot;Times New Roman&quot;, serif;">Primary objectives of this study is to know indications of starting antifungal. Secondary objectives to know Incidence of using antifungal in NICU and outcome of neonates in whom antifungals used. </span><span style="text-align: justify; font-family: &quot;Times New Roman&quot;, serif;">Prophylactic antifungal drugs have been shown to reduce fungal colonisation and infection rates in randomised trials in VLBW babies⁴. In this review we discuss the potential benefits and risks of fungal prophylaxis in VLBW babies</span><span style="text-align: justify; font-family: &quot;Times New Roman&quot;, serif;">.</span><span class="Style1praChar" style="text-align: justify;"><span lang="EN-IN" style="font-size:12.0pt;line-height:150%">The medical case records of all Babies admitted in NICU during the study period were thoroughly analysed for antifungal therapies, indication and day of life when started. The outcome was measured as mortality or discharge</span></span><span style="text-align: justify; font-family: &quot;Times New Roman&quot;, serif;">.Results-Out of total 14 VLBW babies 86% (12) discharged and 14 %( 2) died ,out of 4 ELBW babies 50% discharged and 50% died and total 3 post-operative babies 33% discharged and 67% died. Conclusion-Prophylactic antifungal therapy does not affect the mortality in ELBW&rsquo;s and Post Operated groups.</span></p> <p class="MsoNormal" style="text-align:justify;line-height:150%"><span style="font-family:&#10;&quot;Times New Roman&quot;,serif"><o:p></o:p></span></p>